1. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy 
Sean A. Virani, MD, MSc, MPH, FRCPC, Susan Dent, MD, FRCPC, Christine Brezden-Masley, MD, PhD, FRCPC, Brian Clarke, MD, FRCPC, FACC, Margot K. Davis, MD, FRCPC, Davinder S. Jassal, MD, FACC, FRCPC, Christopher Johnson, MD, FRCPC, Julie Lemieux, MD, MSc, FRCPC, Ian Paterson, MD, FRCPC, Igal A. Sebag, MD, FRCPC, FACC, FASE, Christine Simmons, MD, MSc, FRCPC, Jeffrey Sulpher, MD, FRCPC, Kishore Thain, MD, FRCPC, Paaldinesh Thavendiranathan, MD, MSc, FRCPC, Jason R. Wentzell, BScPharm, ACPR, Nola Wurtele, MN, NP(A), Marc André Côté, MD, FRCPC, Nowell M. Fine, MD, MS, FRCPC, Haissam Haddad, MD, FRCPC, FACC, Bradley D. Hayley, MD, FRCPC, Sean Hopkins, BSc (Hon), BSP, Anil A. Joy, MD, Daniel Rayson, MD, FRCPC, FACP, Ellamae Stadnick, MD, MSc, FRCPC, Lynn Straatman, MD, FRCPC 
Canadian Journal of Cardiology 
Volume 32, Issue 7, Pages (July 2016)
DOI: /j.cjca
Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions

2. Figure 1
Preexisting cardiovascular disease and cardiac risk factors combine with chemotherapy and targeted therapy to produce subclinical and clinical cardiovascular disease, during and long after cancer therapy. This model for cancer therapy-induced cardiotoxicity emphasizes multiple risk factors, each of which is a potential target for intervention. Whether such intervention translates into clinical benefit requires further study.
Modified from Jones et al.6 and Cardinale et al.7 with permission from Elsevier.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2016 Canadian Cardiovascular Society Terms and Conditions